Investigational drug · Phase 3
MDR-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight or Obesity.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "MDR-001"
First trial start
2026
Feb 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MDR-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight or Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MDR-001" as an intervention, largest first.
- A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)Pivotal-lookingNot yet recruiting
MindRank AI LtdIndustry
NCT07274137 · 738 participants (planned) · Start Feb 2026 · Primary completion Jun 2027
Drug: MDR-001; Placebo · For: Overweight or Obesity
Sites: Beijing, China; Changchun, China; Changde, China · 45 sites in all
- A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or OverweightPivotal-lookingStatus unknown
MindRank AI LtdIndustry
NCT06606483 · 300 participants (planned) · Start Sep 23, 2024 · Primary completion Jul 30, 2025
Drug: MDR-001; Placebo · For: Obesity; Overweight and Obesity
Sites: Hefei, China; Xuancheng, China; Zibo, China · 19 sites in all
- A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight ParticipantsPivotal-lookingCompleted
MindRank AI LtdIndustry
NCT06778850 · 128 participants · Start Jun 9, 2023 · Primary completion Jul 15, 2024
Drug: MDR-001; palcebo · For: Overweight and Obese Volunteers
Sites: Changchun, China
MindRank AI LtdIndustry
NCT07550634 · 32 participants (planned) · Start Jun 1, 2026 · Primary completion Jul 8, 2026
Drug: MDR-001 · For: Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B); Hepatic Insufficiency (MeSH ID: D048550)
Sites: Changchun, China
- Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult ParticipantsNot yet recruiting
MindRank AI LtdIndustry
NCT07550621 · 28 participants (planned) · Start May 6, 2026 · Primary completion May 31, 2026
Drug: MDR-001; Rifampin and 1 more · For: Healthy Volunteers (HV)
Sites: Changchun, China
- Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or OverweightNot yet recruiting
MindRank AI LtdIndustry
NCT07110766 · 24 participants (planned) · Start Aug 9, 2025 · Primary completion Sep 15, 2025
Drug: MDR-001; Placebo · For: Obesity &Amp; Overweight
Sites: Ch’ang-ch’un, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight or Obesity
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- BGM0504Phase 35 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity
- TG103Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity
- zovaglutideZT002Phase 33 trials
Beijing QL Biopharmaceutical Co.,Ltd · Obesity, Overweight , Obesity, Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.